Critical Survey: Nanovibronix (FEED) and The Competition

Nanovibronix (NASDAQ:FEED) is one of 29 public companies in the “Surgical, Medical, And Dental Instruments And Supplies” industry, but how does it contrast to its peers? We will compare Nanovibronix to related companies based on the strength of its dividends, earnings, profitability, risk, analyst recommendations, institutional ownership and valuation.

Earnings and Valuation

This table compares Nanovibronix and its peers gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Nanovibronix	$2.56 million	-$3.70 million	-0.07
Nanovibronix Competitors	$59.54 million	-$32.15 million	4.35

Nanovibronix’s peers have higher revenue, but lower earnings than Nanovibronix. Nanovibronix is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Nanovibronix and its peers, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nanovibronix	1	0	0	0	1.00
Nanovibronix Competitors	77	78	158	6	2.29

As a group, “Surgical, Medical, And Dental Instruments And Supplies” companies have a potential upside of 38.17%. Given Nanovibronix’s peers stronger consensus rating and higher possible upside, analysts plainly believe Nanovibronix has less favorable growth aspects than its peers.

Insider and Institutional Ownership

16.4% of Nanovibronix shares are held by institutional investors. Comparatively, 22.5% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by institutional investors. 1.4% of Nanovibronix shares are held by company insiders. Comparatively, 18.1% of shares of all “Surgical, Medical, And Dental Instruments And Supplies” companies are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Risk and Volatility

Nanovibronix has a beta of 2.21, meaning that its share price is 121% more volatile than the S&P 500. Comparatively, Nanovibronix’s peers have a beta of 1.76, meaning that their average share price is 76% more volatile than the S&P 500.

Profitability

This table compares Nanovibronix and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nanovibronix	-275.12%	-24.78%	-19.24%
Nanovibronix Competitors	-672.41%	-133.75%	-59.01%

Summary

Nanovibronix peers beat Nanovibronix on 8 of the 13 factors compared.

About Nanovibronix

NanoVibronix Inc. is a medical device company that is focused on creating medical products utilizing its proprietary low-intensity, surface acoustic wave technology. … NanoVibronix’ catheter-based products include the UroShield™ and NG-Shield™ devices that are both CE mark certified.